{"id":745258,"date":"2015-02-23T17:03:00","date_gmt":"2015-02-23T17:03:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\/"},"modified":"2025-11-07T01:25:22","modified_gmt":"2025-11-07T06:25:22","slug":"merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\/","title":{"rendered":"Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 and 1.875% Convertible Senior Notes Due 2020"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada, on<br \/>\n      behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc.,<br \/>\n      today announced the results of its tender offer (the \u201c<span class=\"bwuline\">Convertible<br \/>\n      Notes Tender Offer<\/span>\u201d) pursuant to which each holder of Cubist\u2019s<br \/>\n      2.50% Convertible Senior Notes due 2017 (the \u201c<span class=\"bwuline\">2017<br \/>\n      Convertible Notes<\/span>\u201d), 1.125% Convertible Senior Notes due 2018<br \/>\n      (the \u201c<span class=\"bwuline\">2018 Convertible Notes<\/span>\u201d) and 1.875%<br \/>\n      Convertible Senior Notes due 2020 (the \u201c<span class=\"bwuline\">2020<br \/>\n      Convertible Notes<\/span>\u201d and together with the 2017 Convertible Notes<br \/>\n      and 2018 Convertible Notes, the \u201c<span class=\"bwuline\">Convertible Notes<\/span>\u201d)<br \/>\n      had the right (the \u201c<span class=\"bwuline\">Fundamental Change Repurchase<br \/>\n      Right<\/span>\u201d), at such holder\u2019s option, to require Cubist to repurchase<br \/>\n      for cash all of such holder\u2019s Convertible Notes, or any portion of the<br \/>\n      principal amount thereof that is equal to $1,000 or an integral multiple<br \/>\n      of $1,000 principal amount, on February 23, 2015. The Fundamental Change<br \/>\n      Repurchase Right expired at the end of the day, immediately after 11:59<br \/>\n      p.m., Eastern time, on February 19, 2015 (the \u201c<span class=\"bwuline\">Fundamental<br \/>\n      Change Expiration Time<\/span>\u201d), and was not extended. Cubist has been<br \/>\n      advised by The Bank of New York Mellon Trust Company, N.A., the Paying<br \/>\n      Agent and Conversion Agent for the Convertible Notes Tender Offer, and<br \/>\n      Mackenzie Partners, the Information Agent for the Convertible Notes<br \/>\n      Tender Offer, that none of the Notes were validly surrendered for<br \/>\n      repurchase prior to the Fundamental Change Expiration Time.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51045591&amp;newsitemid=20150223006525&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=588cff1e92ce36f1070a9476dc8d0add\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51045591&amp;newsitemid=20150223006525&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=0cb6d10a9e25365fa7397859cc332c3e\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=51045591&amp;newsitemid=20150223006525&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=aaa9f35524c00131c381a8bcbc5e7b97\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&amp;esheet=51045591&amp;newsitemid=20150223006525&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=e7dea4a8cf0ab574f8cd7b590c2b6fbc\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the U.S. Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of Merck\u2019s management and are subject<br \/>\n      to significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise except as required by applicable law. Additional factors that<br \/>\n      could cause results to differ materially from those described in the<br \/>\n      forward-looking statements can be found in Merck\u2019s 2013 Annual Report on<br \/>\n      Form 10-K and the company\u2019s other filings with the Securities and<br \/>\n      Exchange Commission (SEC) available at the SEC\u2019s Internet site <span class=\"bwuline\">(<\/span><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51045591&amp;newsitemid=20150223006525&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=020270089a4972ab8922349109fc6725\" rel=\"nofollow\">www.sec.gov<\/a><span class=\"bwuline\">)<\/span>.\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150223006525r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Lainie Keller, (908) 236-5036<br \/>Steve Cragle,        (908) 740-1801<br \/>or<br \/>Investor:<br \/>Joe Romanelli, (908) 740-1986<br \/>Justin        Holko, (908) 740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced the results of its tender offer (the \u201c Convertible Notes Tender Offer \u201d) pursuant to which each holder of Cubist\u2019s 2.50% Convertible Senior Notes due 2017 (the \u201c 2017 Convertible Notes \u201d), 1.125% Convertible Senior Notes due 2018 (the \u201c 2018 Convertible Notes \u201d) and 1.875% Convertible Senior Notes due 2020 (the \u201c 2020 Convertible Notes \u201d and together with the 2017 Convertible Notes and 2018 Convertible Notes, the \u201c Convertible Notes \u201d) had the right (the \u201c Fundamental Change Repurchase Right \u201d), at such holder\u2019s option, to require Cubist to repurchase for cash all of such holder\u2019s Convertible Notes, or any portion of the principal amount thereof that is equal to $1,000 or an integral multiple of $1,000 principal amount, on February 23, 2015. The Fundamental Change Repurchase Right expired at the end of the day, immediately after<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,52,64,289],"class_list":["post-745258","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-financial-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 and 1.875% Convertible Senior Notes Due 2020 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 and 1.875% Convertible Senior Notes Due 2020 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced the results of its tender offer (the \u201c Convertible Notes Tender Offer \u201d) pursuant to which each holder of Cubist\u2019s 2.50% Convertible Senior Notes due 2017 (the \u201c 2017 Convertible Notes \u201d), 1.125% Convertible Senior Notes due 2018 (the \u201c 2018 Convertible Notes \u201d) and 1.875% Convertible Senior Notes due 2020 (the \u201c 2020 Convertible Notes \u201d and together with the 2017 Convertible Notes and 2018 Convertible Notes, the \u201c Convertible Notes \u201d) had the right (the \u201c Fundamental Change Repurchase Right \u201d), at such holder\u2019s option, to require Cubist to repurchase for cash all of such holder\u2019s Convertible Notes, or any portion of the principal amount thereof that is equal to $1,000 or an integral multiple of $1,000 principal amount, on February 23, 2015. The Fundamental Change Repurchase Right expired at the end of the day, immediately after\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:22+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150223006525r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\\\/\",\"name\":\"Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 and 1.875% Convertible Senior Notes Due 2020 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150223006525r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2015-02-23T17:03:00+00:00\",\"dateModified\":\"2025-11-07T06:25:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150223006525r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150223006525r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 and 1.875% Convertible Senior Notes Due 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 and 1.875% Convertible Senior Notes Due 2020 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\/","og_locale":"en_US","og_type":"article","og_title":"Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 and 1.875% Convertible Senior Notes Due 2020 - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced the results of its tender offer (the \u201c Convertible Notes Tender Offer \u201d) pursuant to which each holder of Cubist\u2019s 2.50% Convertible Senior Notes due 2017 (the \u201c 2017 Convertible Notes \u201d), 1.125% Convertible Senior Notes due 2018 (the \u201c 2018 Convertible Notes \u201d) and 1.875% Convertible Senior Notes due 2020 (the \u201c 2020 Convertible Notes \u201d and together with the 2017 Convertible Notes and 2018 Convertible Notes, the \u201c Convertible Notes \u201d) had the right (the \u201c Fundamental Change Repurchase Right \u201d), at such holder\u2019s option, to require Cubist to repurchase for cash all of such holder\u2019s Convertible Notes, or any portion of the principal amount thereof that is equal to $1,000 or an integral multiple of $1,000 principal amount, on February 23, 2015. The Fundamental Change Repurchase Right expired at the end of the day, immediately after","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:22+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150223006525r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\/","name":"Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 and 1.875% Convertible Senior Notes Due 2020 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150223006525r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","datePublished":"2015-02-23T17:03:00+00:00","dateModified":"2025-11-07T06:25:22+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150223006525r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150223006525r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-results-of-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-du\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 and 1.875% Convertible Senior Notes Due 2020"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"9b776f2f-b2f7-4977-954b-393304e53d68","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745258\/revisions"}],"predecessor-version":[{"id":3674682,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745258\/revisions\/3674682"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745258"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}